Teva to Present Latest Data on AJOVY (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that eight abstracts examining real-world data to better understand the use of AJOVY (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.

The data presented at this year’s AHS meeting will focus on real-world use of AJOVY across different patient populations. Featured data will include a late-breaking poster presentation on real-world evidence in patients using concomitant gepants for acute migraine treatment, as well as results of a subgroup analysis from the Phase 3b FOCUS study examining the use of AJOVY in patients with difficult-to-treat migraine and comorbid obesity. In addition, a real-world effectiveness study of AJOVY in patients with refractory migraine who switched from erenumab will be highlighted at the meeting.

“June is Migraine and Headache Awareness month, a time that reminds us that while there have been many advances recently in the migraine treatment landscape, there is still work to be done,” said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. “At this year’s AHS meeting, we are looking forward to presenting new real-world research that underscores the impact AJOVY can have on people with specific migraine treatment needs across different clinical circumstances.”

This year’s annual AHS meeting is being offered both in person and virtually. Data presentations can be accessed by registering for the meeting.

The full set of Teva-sponsored AJOVY data to be presented includes:

Late-breaking:

• Real-World Effectiveness and Tolerability of Fremanezumab for the Preventive Treatment of Migraine in Patients Using Concomitant Gepants for Acute Treatment in a US Neurology Practice (TGT-72562)

De novo:

• Real-World Effectiveness of Fremanezumab in Patients with Refractory Migraine from a US Tertiary Headache Center Who Switched from Erenumab (TGT-72532)
• Real-World Reductions in Migraine-Related Healthcare Resource Utilization and Medication Use with Fremanezumab Treatment in US Migraine Patients Using Concomitant Acute Gepants (TGT-72533)
• Real-World Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities, Acute Medication Overuse, or Difficult-to-Treat Migraine (TGT-72549)
• Reductions in Acute Medication Use, Migraine-Related Health Care Resource Utilization, and Costs for Patients Initiating Fremanezumab: Results of a Long-Term US Claims Database Analysis (TGT-72550)
• Efficacy and Safety of Fremanezumab in Patients with Obesity and Difficult-to-Treat Migraine: Subgroup Analysis of the Randomized, Double-Blind, Phase 3B FOCUS Study (TGT-72561)
• Primary Headache Disorders and Acute Abortive Medications Associated with Patients Diagnosed with Medication Overuse Headache: Analysis of German EMR Data (TGT-73146)

Encore: